Pulmonary Alveolar Microlithiasis Medical Services in China

Pulmonary alveolar microlithiasis (PAM) is a rare, chronic, autosomal recessive lung disorder characterized by the intra-alveolar accumulation of calcium phosphate microliths. Caused by mutations in the SLC34A2 gene, it leads to dysfunctional surfactant metabolism and progressive mineral deposition within alveoli. Symptoms—often insidious—include dyspnea on exertion, dry cough, and fatigue; many patients remain asymptomatic for years despite radiographic evidence of diffuse “sandstorm” or “ground-glass” opacities on high-resolution CT. Diagnosis relies on characteristic imaging, bronchoalveolar lavage showing calcified microliths, and genetic confirmation. No disease-modifying pharmacotherapy exists; management focuses on supportive care, oxygen therapy, and, in advanced cases, lung transplantation—the only potentially curative intervention. Prognosis varies widely: some patients maintain stable function for decades, while others progress to respiratory failure.

China offers distinct advantages for PAM management. Leading respiratory centers—including Beijing Tongren Hospital, Shanghai Ruijin Hospital, and Guangzhou Institute of Respiratory Health—house multidisciplinary teams with deep expertise in rare interstitial lung diseases and extensive experience in pre-transplant evaluation and post-transplant immunomodulation. Advanced imaging (dual-energy CT), next-generation sequencing for SLC34A2 variants, and ex vivo lung perfusion systems enhance diagnostic precision and transplant feasibility. Over 30 successful lung transplants for PAM have been documented in Chinese centers since 2018, with 1-year survival rates exceeding 85%. Treatment costs—including comprehensive workup, transplant, and 6-month follow-up—are typically 40–60% lower than in the US or EU, without compromising quality or outcomes.

As a dedicated medical tourism agency, we facilitate seamless access to these resources for international patients: coordinating referrals with top-tier hospitals, providing itemized, transparent pricing in advance, arranging visa support, accommodation, interpreter services, and post-discharge telehealth follow-up—all tailored to individual clinical and logistical needs.

Medical Travel to China Guide: Pulmonary Alveolar Microlithiasis (PAM) Patients seeking diagnosis or management for PAM in China must obtain a Medical Visa (Q2 or S2, depending on duration and companion status), supported by an official invitation letter from the treating hospital—our agency secures this within 3–5 business days. All travelers require valid passports, completed visa applications, and proof of return travel. Regarding medical insurance, most international policies exclude overseas treatment; we partner with select insurers for pre-authorization and offer transparent, itemized quotes before your trip—no hidden fees. Payments can be made securely via bank transfer, credit card, or WePay, with receipts provided in English. We arrange comfortable, hospital-proximate accommodations (including apartment-style options for extended stays) and assist with visa documentation for one companion. Post-consultation, our dedicated care coordinators schedule follow-up teleconsultations with your Chinese pulmonologist every 4–6 weeks, share digital copies of reports and imaging, and help interpret results alongside your home physician. We also support medication sourcing and shipping coordination where permitted. Let us handle logistics while you focus on care.